Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) CEO Jeffrey M. Leiden sold 99,563 shares of Vertex Pharmaceuticals stock in a transaction that occurred on Tuesday, January 16th. The stock was sold at an average price of $156.99, for a total transaction of $15,630,395.37. Following the completion of the transaction, the chief executive officer now owns 176,747 shares of the company’s stock, valued at approximately $27,747,511.53. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) opened at $156.99 on Thursday. The company has a market cap of $39,379.50, a price-to-earnings ratio of 201.27, a PEG ratio of 1.84 and a beta of 1.58. Vertex Pharmaceuticals Incorporated has a 1-year low of $80.06 and a 1-year high of $167.85. The company has a debt-to-equity ratio of 0.01, a current ratio of 3.28 and a quick ratio of 3.14.

Vertex Pharmaceuticals (NASDAQ:VRTX) last announced its earnings results on Wednesday, October 25th. The pharmaceutical company reported $0.53 EPS for the quarter, beating analysts’ consensus estimates of $0.04 by $0.49. The business had revenue of $578.20 million for the quarter, compared to analysts’ expectations of $522.07 million. Vertex Pharmaceuticals had a net margin of 8.53% and a return on equity of 9.23%. The company’s quarterly revenue was up 39.7% on a year-over-year basis. During the same period in the previous year, the company posted $0.16 EPS. analysts predict that Vertex Pharmaceuticals Incorporated will post 0.76 earnings per share for the current fiscal year.

VRTX has been the subject of a number of recent research reports. Cowen reiterated a “buy” rating and issued a $200.00 price target on shares of Vertex Pharmaceuticals in a research note on Monday, December 11th. Deutsche Bank started coverage on shares of Vertex Pharmaceuticals in a report on Tuesday, December 12th. They set a “buy” rating and a $175.00 price objective on the stock. Zacks Investment Research cut shares of Vertex Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, October 24th. Royal Bank of Canada raised their price objective on shares of Vertex Pharmaceuticals from $175.00 to $181.00 and gave the stock an “outperform” rating in a report on Wednesday, October 18th. Finally, Vetr cut shares of Vertex Pharmaceuticals to a “sell” rating in a report on Thursday, September 21st. One analyst has rated the stock with a sell rating, three have assigned a hold rating, twenty-five have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus price target of $175.89.

Several institutional investors have recently made changes to their positions in VRTX. Jennison Associates LLC increased its holdings in shares of Vertex Pharmaceuticals by 19.0% in the 3rd quarter. Jennison Associates LLC now owns 6,017,766 shares of the pharmaceutical company’s stock valued at $914,941,000 after acquiring an additional 962,644 shares during the period. Point72 Asset Management L.P. increased its holdings in shares of Vertex Pharmaceuticals by 8,061.1% in the 3rd quarter. Point72 Asset Management L.P. now owns 909,230 shares of the pharmaceutical company’s stock valued at $138,239,000 after acquiring an additional 898,089 shares during the period. Assenagon Asset Management S.A. increased its holdings in shares of Vertex Pharmaceuticals by 9,422.3% in the 3rd quarter. Assenagon Asset Management S.A. now owns 893,380 shares of the pharmaceutical company’s stock valued at $135,829,000 after acquiring an additional 883,998 shares during the period. Vanguard Group Inc. increased its holdings in shares of Vertex Pharmaceuticals by 3.1% in the 2nd quarter. Vanguard Group Inc. now owns 16,979,872 shares of the pharmaceutical company’s stock valued at $2,188,196,000 after acquiring an additional 504,982 shares during the period. Finally, Fred Alger Management Inc. increased its holdings in shares of Vertex Pharmaceuticals by 34.3% in the 2nd quarter. Fred Alger Management Inc. now owns 1,624,480 shares of the pharmaceutical company’s stock valued at $209,347,000 after acquiring an additional 414,501 shares during the period. 93.19% of the stock is currently owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY WARNING: This story was posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this story on another publication, it was illegally stolen and reposted in violation of US and international trademark and copyright law. The legal version of this story can be read at https://www.thecerbatgem.com/2018/01/18/jeffrey-m-leiden-sells-99563-shares-of-vertex-pharmaceuticals-incorporated-vrtx-stock.html.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated is engaged in discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications.

Insider Buying and Selling by Quarter for Vertex Pharmaceuticals (NASDAQ:VRTX)

Receive News & Ratings for Vertex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.